New molecule approved by USFDA tilldate in 2014
Posted on27 Oct 2014
Comments0
2014 New Molecule Approved tilldate No. Drug Name Active Ingredient Date What It’s Used For 34 Esbriet pirfenidone 15-10-2014 For the treatment of... Read More
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
new molecule approved by USFDA in 2014
Our Popular Courses
Recent Articles
- Pharma acquisition case study: Lundbeck to acquire Alder BioPharmaceuticals for US$ 1.95 billion
- Insight on submission of USFDA sBLA of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)
- Mitsubishi Tanabe Pharma, Daiichi Sankyo enters licensing agreement for ALS treatment agent edaravone in Brazil
- Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
- Insight on Boehringer Ingelheim’s new indication approval for Ofev to slow the rate of decline in pulmonary function in patients with Ssc-ILD
- Sanofi India announces sale of its Ankleshwar facility to Zentiva
- What are DACH region? Which countries are part of DACH region?
- Strides Pharma acquires stake in Fairmed Healthcare for extensive growth in DACH region
- GSK to acquire Celiac-Focused Sitari Pharmaceuticals
- Takeda recalled of NATPARA (a parathyroid hormone) in US
- Sandoz to commercialize proposed multiple sclerosis biosimilar natalizumab
- Boehringer Ingelheim’s KRAS and Lupin’s MEK inhibitor compound (LNP3794) – Licensing, development and Commercialization Agreement
- Sumitomo Dainippon and Roivant’s strategic alliance to develop new medicine
- GSK, INNOVAX and Xiamen University’s Global co-developmennt alliance for cervical cancer vaccine
- Insight on USFDA approval of new add-on drug, Nourianz (istradefylline), to treat off episodes in adults with Parkinson’s disease
- Pharma brand acquisition case study: Amgen to acquire Celgene’s Otezla
- Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
- GSK grants exclusive technology license for Ebola vaccines to Sabin Vaccine Institute
- Turalio: USFDA approval of first therapy for rare joint tumor
- Case Study: The Mylan-Upjohn,Pfizer Merger